The new issue of shares in FarmPharma via FundedByMe is closed
Today, 26 september the Board of FarmPharma AB, a wholly-owned subsidiary of Double Bond Pharmaceutical, has closed the new issue via FundedByMe. 83 investors participated in the rights issue which brought 770 000 SEK. 77 001 new shares in FarmPharma were issued. Upon registration total number of shares in FarmPharma AB will be 1 077 001 and total share capital will amount to sek 53 850,05.
"I am pleased to welcome new shareholders to FarmPharma, but also grateful that our existing DBP shareholders have shown us continued confidence by becoming the main owner of FarmPharma," commented Igor Lokot, CEO of both DBP and FarmPharma. FarmPhama's concept will get great importance in the future as the need to reduce overuse of antibiotics is high. "
Double Bond Pharmaceutical ownership, after registration of the rights issue, is 93% of votes and capital.
More about crowd funding campaign: https://mb.cision.com/Main/12720/2553815/863655.pdf
More about FarmPharma: FarmPharma AB is a wholly-owned subsidiary of Double Bond Pharmaceutical. The company is active in the development and distribution of veterinary products, and their first product is for the prevention and treatment of bacterial and viral infections in cattle without the use of antibiotics. For more info: http://www.farmpharma.se/ ____________________________________________________________________
Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Blog: http://blog.doublebp.com
Follow us on LinkedIn (https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one) and Twitter (https://twitter.com/DoubleBondPharm)!
_______________________________________________________________________________
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.